News >

CAR T-Cell Therapy Shows Promise in Relapsed/Refractory Myeloma

Angelica Welch
Published: Monday, Jan 29, 2018

Jesus Berdeja, MD

Jesus Berdeja, MD
The second-generation BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy bb2121 induced complete remissions (CRs) in 56% of patients with relapsed or refractory multiple myeloma, providing a potentially promising option for a heavily pretreated population.

during the 2017 ASH Annual Meeting, lead investigator Jesus Berdeja, MD, director of Multiple Myeloma Research at Sarah Cannon Research Institute, discussed ongoing research with bb2121 in patients with relapsed/refractory myeloma.

OncLive: Can you provide an overview of the study of bb2121 in myeloma presented at ASH?

Berdeja: bb2121 is a CAR-T product directed at BCMA that uses a 4-1BB costimulatory domain and it is for patients with relapsed/refractory multiple myeloma. We presented the completed phase I dose-escalation portion of the trial. We have started the dose-expansion, but we are not presenting those data just yet. Twenty-four patients were accrued and 21 patients were infused with the CAR T cells, so only 3 patients actually deteriorated. This is a patient population that is very heavily pretreated, with 7 median prior lines of therapy; they had basically exhausted all other treatments. It is quite impressive that only 3 patients were not able to move through.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication